Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.
Although the event rate did reach the expected level and longer follow-up is needed to adequately assess long-term toxicities, data from the phase 3 IELSG37 trial support the omission of radiotherapy in patients with primary mediastinal large B-cell lymphoma who achieve a complete metabolic response following chemoimmunotherapy.